Tumour response is defined according to WHO or RECIST criteria and classified into overall response (complete or partial response), stable disease, and progressive disease.
In the control group, overall adherence (full or partial) to infection control precautions was observed in 38% of transfers involving an infectious patient.
The overall rates of synergy or partial synergy for aztreonam with fluoroquinolone combinations was 63.4% versus P. aeruginosa, greatest for aztreonam with gatifloxacin (67.5%).
The primary endpoint was overall response rate (complete or partial response as best response).
Objective response rate represents the proportion of patients with a best overall response of complete or partial response.
There was no relationship between overall response (either complete or partial remission) and the presence or absence of hypogammaglobulinaemia (IgG < 6 g/l).
Association of the overall response rate (complete or partial response) with the investigated tumour proliferation markers is shown in Table 4.
Accordingly, a Phase 1 trial with an extension cohort reported 81% overall response rate (complete or partial response) in mutated patients (Flaherty et al, 2010).
ORR was estimated as the proportion of patients who received any dose of bendamustine, defined for this single-arm study as the intent-to-treat (ITT) population, with the best overall response of CR or partial response (PR).
The primary endpoint, overall response rate (complete or partial response), was 36%95%5% CI 17 59%) in the capecitabine group and 26%95%5% CI 9 51%) in the paclitaxel group (not statistically different).
Overall, partial or complete recanalization was observed in 24 (92%) of 26 vessels treated with a single pass of the MTD.> There were no major complications associated with the MTD thrombectomy procedure, including vascular perforation, intramural arterial dissection, distal embolization from an embolic fragment, hemorrhage, or access site injury.
